Untenstehend finden Sie unsere Liste der Practice Changing Studies (PCS). Wir führen sie erstmals für das Jahr 2018 auf und werden sie in den kommenden Jahren laufend updaten.

Für Beupdated ist eine «Practice Changing Study» eine Studie, von der unsere Experten der Meinung sind, dass Patienten direkt darüber informiert werden sollten, weil sie eine wesentliche Verbesserung des bisherigen Behandlungsstandards darstellt (Dabei ist gut möglich, dass für die neue Behandlung noch keine Kassenzulässigkeit besteht). Practice Changing kann bedeuten, dass sich durch die neue Behandlung die Prognose, oder aber die Lebensqualität des Patienten, verbessert.

Beupdated ist es wichtig, dass man festlegt, was für Schweizer Opinion Leaders im Bereich der Medizinischen Onkologie Practice Changing ist, obwohl gewisse Studien sich in einer Grauzone bewegen und von denen nur die Zeit zeigen kann, ob sie wirklich einen Practice Change darstellen oder nicht. Solche Studien reevaluieren wir in regelmässigen Abständen und passen die Liste immer wieder neu an.

Die Liste befindet sich zurzeit noch im Aufbau und ist deshalb eventuell noch nicht ganz vollständig.

 

PCS 2019

Kongress Indikation Studienname und Referenz / Link
ASCO GI Esophagus Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study
ASCO GI Biliary tract Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): a cohort of the ROAR basket trial

 

PCS 2018

Kongress Indikation Studienname und Referenz / Link
SABCS Breast Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE
ASH Lymphoma Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE
Kongress Indikation Studienname und Referenz / Link
SABCS Breast Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE
ASH Lymphoma Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE
ASH Leukemia 6 Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergro
ASH Leukemia LBA-4 A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN C
ASH Lymphoma AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
ASH Lymphoma The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas
ASH Myeloma Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
ASH Myeloma LBA-2 Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)
ASH Lymphoma Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLAClinically Relev
ESMO GI TAGS, a randomized, double-blind, phase 3 study evaluating TAS-102 plus best supportive care vs placebo plus best supportive care in patients with metastatic gastric cancer refractory to standard treatments
ESMO Anal InterAACT, a multicenter open label randomized phaseII trial of cisplatin (CDDP) plus 5 fluorouracil (5FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients with inoperable locally recurrent or metastatic treatment naive disease – an international
ESMO Prostate Radiotherapy for newly diagnosed oligometastatic prostate cancer
ESMO Renal Cell JAVELIN Renal 101: a randomized, phase 3 study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)
ESMO Breast IMpassion130: Results from a global, randomised, double-blind, Phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in treatment-naive locally advanced or metastatic triple-negative breast cancer
ESMO Ovary Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
ASCO Breast Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
ASCO Renal CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial
ASCO GI Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas
ASCO Breast PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results
ASCO Breast Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT
ASCO Lung Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC)
ASCO Lung IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC
ASCO Lung Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227